Course book Advanced Treatment Planning 2018

DOSE CONSTRAINTS LUNGTECH TRIAL: SUMMARY

Unaccep- table variation EqD2 in Gy

αβ in Gy

Acceptable variation in Gy

Acceptable variation EqD2 in Gy

Unacceptable variation in Gy

D max in Gy

EqD2 in Gy

OAR

Trachea/ Main bronchus 3 8*5.5= 44

74.8 <8*5.81=46.68 < 81.9

≥8*5.81=46.68

>81.9

Heart §

3 3

Great vessels §

Oesphagus

3 8*5 = 40

64

<8*5.44=43.52 <73.6

≥8*5.44=43.52 >8*4=32 ≥8*5.17=41.36 ≥8*7.785=62.28

≥73.6

Spinal cord & Brachial plexus &

2 3 3 3 3

8*4 = 32 8*4.75=38 8*7.5= 60

48 58.9 126

>48 ≥67.7 ≥134.2

<8*5.17=41.36 <8*7.785=62.28

< 67.7

Body-PTV & Lung-CTV § Chest wall §

<134.2

& for <0.5 cc § no restrictions are provided but recording of DVH data for toxicity evaluation is required

EORTC 22113-0813-Lu ngTe ch RTQA Guidelines

Adebahr et al , BJR 2015

German Cancer Consortium (DKTK)